Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management. Medscape: Comparison of Renal Effects of Ibuprofen versus Indomethacin during Treatment of Patent Ductus Arteriosus in Contiguous Historical Cohorts Background Ibuprofen treatment of patent ductus arteriosus (PDA) has been shown to be as effective as indomethacin in small randomized controlled trials, with possibly fewer adverse effects. However, ...
Comparison of Renal Effects of Ibuprofen versus Indomethacin during Treatment of Patent Ductus Arteriosus in Contiguous Historical Cohorts The New England Journal of Medicine: Early Treatment of Patent Ductus Arteriosus with Ibuprofen For extremely preterm infants who have a large patent ductus arteriosus, early treatment with ibuprofen may reduce the risk of death and improve short-term outcomes. New research findings are ... The Society for Cardiovascular Angiography & Interventions (SCAI) has published a new position statement that provides best-practice guidance for the treatment of patent ductus arteriosus (PDA) using ... Patent ductus arteriosus (PDA) remains a prominent clinical challenge in the management of preterm infants.
patent ductus arteriosus treatment, During fetal life, the ductus arteriosus diverts blood away from the underdeveloped lungs, ... MedPage Today: Preterm Infants Treated Early for Patent Ductus Arteriosus Had Worse Outcomes The multicentre, randomised, double-blind, placebo-controlled Baby-OSCAR trial. Participants were 653 extremely preterm infants with a large patent ductus arteriosus (diameter, ≥ 1.5 mm). In the first ... Nasdaq: Merit Medical Systems Initiates PREEMIE Study on Bloom Micro Occluder System for Treating Patent Ductus Arteriosus in Premature Infants Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants.
patent ductus arteriosus treatment, Merit Medical Systems, Inc. has announced the enrollment ... Merit Medical Systems Initiates PREEMIE Study on Bloom Micro Occluder System for Treating Patent Ductus Arteriosus in Premature Infants EurekAlert!: SCAI releases new guidance to improve safety and outcomes of patent ductus arteriosus (PDA) closure in premature infants SCAI releases new guidance to improve safety and outcomes of patent ductus arteriosus (PDA) closure in premature infants
